Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efimosfermin alfa in compensated cirrhosis due to MASH
NCT07704892Phase 3Recruiting
- Sponsor
- GSK
- Start
- Jul 2026
- Primary completion
- Oct 2030
- Countries
- 2
01
Overview
A Phase 3 trial of efimosfermin in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by GSK. Started Jul 2026; status: recruiting.
02
Drugs
efimosfermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07704892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07704892.